Seroquel XR;治療藥物分析及市場預測 是由出版商GlobalData在2011年07月所出版的。
這份英文市場調查報告書包含Pages: 29 價格從美金2000起跳。
本報告提供精神分裂症治療藥物的 Seroquel XR 平台分析及市場預測，以市場特徵為首，評估分析競爭，開發平台等，加上未來市場競爭，企業簡介等資料，為您概述為以下內容。
1 目錄 1 目錄 2 簡介
- 2.1 精神分裂症
- 2.2 症狀
- 2.3 精神分裂症 市場
- 2.4 免疫學
- 2.5 病因論
- 2.5.1 遺傳的因素
- 2.5.2 環境的因素
- 2.5.3 腦結構的異常
- 2.6 GlobalData 報告指南
3 精神分裂症: 市場特性
- 3.1 精神分裂症 市場
- 3.2 精神分裂症 市場 預測及年複合成長率
- 3.3 推動力; 精神分裂症 治療藥物市場
- 3.3.1 專利期間的結束; 主要上市藥
- 3.3.2 病患族群的增加
- 3.3.3 高處方率
- 3.3.4 低的患者藥物服用遵守率
- 3.3.5 高未飽和需求
4 分類; 精神分裂症
- 4.1 發病年齡 精神分裂症
- 4.1.1 小兒 / 青年時期 / 幼年期 精神分裂症
- 4.1.2 大人的 精神分裂症
- 4.2 相關症狀
- 4.2.1 妄想型精神分裂症
- 4.2.2 錯亂型精神分裂症
- 4.2.3 緊張型精神分裂症
- 4.2.4 殘餘型精神分裂症
- 4.2.5 未分類症狀疾患
5 治療方法; 精神分裂症
- 5.1 危機解決團隊 (CRT)
- 5.2 自願及強制的逗留
- 5.3 抗精神病藥
- 5.3.1 典型抗精神病藥物
- 5.3.2 A典型抗精神病藥物
- 5.3.3 死亡率的增加 - 患有癡呆症相關的精神病的高齡患者
6 Seroquel XR
- 6.1 簡介
- 6.2 作用機制
- 6.3 臨床研究
- 6.4 銷售額的影響因素; Seroquel XR
- 6.4.1 服用的便利性
- 6.4.2 病患族群的增加
- 6.4.3 日本的緩慢認證; Seroquel XR
- 6.5 醫藥品評估
- 6.5.1 藥物的風險·好處評估
- 6.5.2 競爭激烈度
- 6.6 銷售額預測
- 6.6.1 標的病患族群; Seroquel XR
- 6.6.2 投藥
- 6.6.3 市場滲透率
- 6.6.4 治療的年度成本;
- 6.6.5 銷售額預測; Seroquel XR
7 精神分裂症 市場: 附錄
- 7.1 市場定義
- 7.2 簡稱
- 7.3 調查方法
- 7.4 治療藥物的銷售額預期模式
- 7.5 諮詢方式
- 7.6 免責聲明
- 7.7 資訊來源
1.1 表格一覽
- 表格 1: 藥物的風險·優勢評估; Seroquel XR
- 表格 2: Seroquel XR, 精神分裂症, 全球市場, 銷售額預測 ($m)
- 表格 3: Seroquel XR, 精神分裂症, 美國, 銷售額預測 ($m)
- 表格 4: Seroquel XR, 精神分裂症, 英國, 銷售額預測 ($m)
- 表格 5: Seroquel XR, 精神分裂症, 法國, 銷售額預測 ($m)
- 表格 6: Seroquel XR, 精神分裂症, 德國, 銷售額預測 ($m)
- 表格 7: Seroquel XR, 精神分裂症, 義大利, 銷售額預測 ($m)
- 表格 8: Seroquel XR, 精神分裂症, 西班牙, 銷售額預測 ($m)
1.2 圖表一覽
- 圖 1: 進展的風險; 精神分裂症
- 圖 2: 環境的因素 - 精神分裂症的發病
- 圖 3: 精神分裂症, 全球市場, 市場 規模 預測 ($bn)
- 圖 4: 分類; 精神分裂症 (發病年齡為基礎的)
- 圖 5: PANSS 綜合評分的改善; Seroquel XR
- 圖 到6: 復發為止的時間; Seroquel XR
- 圖 7: Drug model diagram; Seroquel XR
- 圖 8: Seroquel XR, 精神分裂症, 全球市場, 銷售額預期($m)
- 圖 9: Seroquel XR, 精神分裂症, 美國, 銷售額預期($m)
- 圖 10: Seroquel XR, 精神分裂症, 英國, 銷售額預期($m)
- 圖 11: Seroquel XR, 精神分裂症, 法國, 銷售額預期($m)
- 圖 12: Seroquel XR, 精神分裂症, 德國, 銷售額預期($m)
- 圖 13: Seroquel XR, 精神分裂症, 義大利, 銷售額預期($m)
- 圖 14: Seroquel XR, 精神分裂症, 西班牙, 銷售額預期($m)
- 圖 15: Seroquel XR, 精神分裂症, 全球市場, 銷售額分佈預測 (%)
Abstract
Summary
GlobalData's pharmaceuticals report, "Seroquel XR - Analysis and Estimates from 2007 to 2020" provides Seroquel XR sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Seroquel XR including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Seroquel XR including efficacy, safety, pricing and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Seroquel XR in each of the seven major markets
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of contents
1. Table of contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Introduction
- 2.1 Schizophrenia
- 2.2 Symptoms
- 2.3 Schizophrenia Market
- 2.4 Epidemiology
- 2.5 Etiology
- 2.5.1 Genetic Factors
- 2.5.2 Environmental Factors
- 2.5.3 Abnormal Brain Structure
- 2.6 GlobalData Report Guidance
3. Schizophrenia: Market Characterization
- 3.1 Schizophrenia Market
- 3.2 Schizophrenia Market Forecasts and CAGR
- 3.3 Drivers of Schizophrenia Therapeutics Market
- 3.3.1 Patent Expiry of Leading Marketed Drugs
- 3.3.2 Increasing Patient Pool
- 3.3.3 High Prescription Rates
- 3.3.4 Low Patient Compliance Rate
- 3.3.5 High Unmet Need
4. Classification of Schizophrenia
- 4.1 Age of Onset of Schizophrenia
- 4.1.1 Pediatric / Adolescent / Childhood Schizophrenia
- 4.1.2 Adult Schizophrenia
- 4.2 Associated Symptoms
- 4.2.1 Paranoid Schizophrenia
- 4.2.2 Disorganized Schizophrenia
- 4.2.3 Catatonic Schizophrenia
- 4.2.4 Residual Schizophrenia
- 4.2.5 Undifferentiated Disorder
5. Treatment for Schizophrenia
- 5.1 Crisis Resolution Teams (CRT)
- 5.2 Voluntary and Compulsory Detention
- 5.3 Antipsychotics
- 5.3.1 Typical Antipsychotics
- 5.3.2 Atypical Antipsychotics
- 5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis
6. Seroquel XR
- 6.1 Introduction
- 6.2 Mechanism of Action
- 6.3 Clinical Studies
- 6.4 Factors Affecting Sales of Seroquel XR
- 6.4.1 Dosing Convenience
- 6.4.2 Increasing Patient Pool
- 6.4.3 Late Approval of Seroquel XR in Japan
- 6.5 Drug Evaluation
- 6.5.1 Drug Risk Benefit Score
- 6.5.2 Intensity of Competition
- 6.6 Sales Forecasts
- 6.6.1 Target Patient Pool of Seroquel XR
- 6.6.2 Dosing
- 6.6.3 Market Penetration
- 6.6.4 Annual Cost of Therapy
- 6.6.5 Sales Projections of Seroquel XR
7. Schizophrenia Market: Appendix
- 7.1 Market Definitions
- 7.2 Abbreviations
- 7.3 Research Methodology
- 7.4 Drug Sales Estimates Model
- 7.5 Contact Us
- 7.6 Disclaimer
- 7.7 Sources
List of Tables
- Table 1: Drug Risk Benefit Score of Seroquel XR
- Table 2: Seroquel XR, Schizophrenia, Global, Sales Forecasts ($m), 2007-2020
- Table 3: Seroquel XR, Schizophrenia, The US, Sales Forecasts ($m), 2007-2020
- Table 4: Seroquel XR, Schizophrenia, The UK, Sales Forecasts ($m), 2008-2020
- Table 5: Seroquel XR, Schizophrenia, France, Sales Forecasts ($m), 2008-2020
- Table 6: Seroquel XR, Schizophrenia, Germany, Sales Forecasts ($m), 2008-2020
- Table 7: Seroquel XR, Schizophrenia, Italy, Sales Forecasts ($m), 2008-2020
- Table 8: Seroquel XR, Schizophrenia, Spain, Sales Forecasts ($m), 2008-2020
List of Figures
- Figure 1: Risk of Developing Schizophrenia
- Figure 2: Environmental Factors in the Development of Schizophrenia
- Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 2010-2020
- Figure 4: Classification of Schizophrenia based on the Age of Disease Onset
- Figure 5: Improvement in PANSS Total Score with Seroquel XR
- Figure 6: Time To Relapse with Seroquel XR
- Figure 7: Drug Model Diagram of Seroquel XR
- Figure 8: Seroquel XR, Schizophrenia, Global, Sales Estimates($m), 2007-2020
- Figure 9: Seroquel XR, Schizophrenia, The US, Sales Estimates($m), 2007-2020
- Figure 10: Seroquel XR, Schizophrenia, The UK, Sales Estimates($m), 2008-2020
- Figure 11: Seroquel XR, Schizophrenia, France, Sales Estimates($m), 2008-2020
- Figure 12: Seroquel XR, Schizophrenia, Germany, Sales Estimates($m), 2008-2020
- Figure 13: Seroquel XR, Schizophrenia, Italy, Sales Estimates($m), 2008-2020
- Figure 14: Seroquel XR, Schizophrenia, Spain, Sales Estimates($m), 2008-2020
- Figure 15: Seroquel XR, Schizophrenia, Global, Sales Distribution (%), 2017
|
